Gynecologic Cancer Treatment
Gynecologic Treatment Using Cesium-131 Provides the Following Advantages:
Deliver the dose where you want. When it's needed.
- Cesium-I3I has delivered 90% of the intended dose 33 days post implant, compared to
32% of the I-125 dose.
- Cesium-I3I has delivered 99.8% of the dose at 90 days, when the sutures/mesh have most
likely dissolved, compared to 65% for I-125.
- Once the carrier material has dissolved, the seeds are free to migrate and stop
contributing to the prescription dose plan.
- Cesium-I3I delivers uniform and symmetrical radiation penetration for a homogeneous
Click here for collaboration with UK Heathcare information.